Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Preterm Birth and PROM Testing Market, By Test Type
7.1. Preterm Birth and PROM Testing Market, By Test Type, 2020-2030
7.1.1. Pelvic exam
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Ferning Test
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. Nitazine Test
7.1.3.1. Market Revenue and Forecast (2016-2030)
7.1.4. Pooling (Speculum Exam)
7.1.4.1. Market Revenue and Forecast (2016-2030)
7.1.5. Ultrasound
7.1.5.1. Market Revenue and Forecast (2016-2030)
7.1.6. Uterine Monitoring
7.1.6.1. Market Revenue and Forecast (2016-2030)
7.1.7. IL-6
7.1.7.1. Market Revenue and Forecast (2016-2030)
7.1.8. CRP
7.1.8.1. Market Revenue and Forecast (2016-2030)
7.1.9. IL-1, IL-2, IL-8, TNF-a
7.1.9.1. Market Revenue and Forecast (2016-2030)
7.1.10. CRH
7.1.10.1. Market Revenue and Forecast (2016-2030)
7.1.11. AFP (Alpha fetoprotein)
7.1.11.1. Market Revenue and Forecast (2016-2030)
7.1.12. fFN
7.1.12.1. Market Revenue and Forecast (2016-2030)
7.1.13. PAMG-1 Immunoassay
7.1.13.1. Market Revenue and Forecast (2016-2030)
7.1.14. IGFBP Test
7.1.14.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Preterm Birth and PROM Testing Market, Regional Estimates and Trend Forecast
8.1. North America
8.1.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.1.2. U.S.
8.1.3. Rest of North America
8.1.3.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.2. Europe
8.2.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.2.2. UK
8.2.2.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.2.3. France
8.2.3.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.2.4. Rest of Europe
8.2.4.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.3. APAC
8.3.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.3.2. India
8.3.2.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.3.3. China
8.3.3.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.3.4. Japan
8.3.4.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.3.5. Rest of APAC
8.3.5.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.4. MEA
8.4.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.4.2. GCC
8.4.2.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.4.3. North Africa
8.4.3.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.4.4. South Africa
8.4.4.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.4.5. Rest of MEA
8.4.5.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.5. Latin America
8.5.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.5.2. Brazil
8.5.2.1. Market Revenue and Forecast, By Test Type (2016-2030)
8.5.3. Rest of LATAM
8.5.3.1. Market Revenue and Forecast, By Test Type (2016-2030)
Chapter 9. Company Profiles
9.1. Qiagen
9.1.1. Company Overview
9.1.2. Product Offerings
9.1.3. Financial Performance
9.1.4. Recent Initiatives
9.2. Hologic
9.2.1. Company Overview
9.2.2. Product Offerings
9.2.3. Financial Performance
9.2.4. Recent Initiatives
9.3. Cooper Surgical
9.3.1. Company Overview
9.3.2. Product Offerings
9.3.3. Financial Performance
9.3.4. Recent Initiatives
9.4. Abbott Laboratories
9.4.1. Company Overview
9.4.2. Product Offerings
9.4.3. Financial Performance
9.4.4. Recent Initiatives
9.5. Medixbiochemica
9.5.1. Company Overview
9.5.2. Product Offerings
9.5.3. Financial Performance
9.5.4. Recent Initiatives
9.6. Sera Prognostics
9.6.1. Company Overview
9.6.2. Product Offerings
9.6.3. Financial Performance
9.6.4. Recent Initiatives
9.7. Biosynex
9.7.1. Company Overview
9.7.2. Product Offerings
9.7.3. Financial Performance
9.7.4. Recent Initiatives
9.8. IQ Products
9.8.1. Company Overview
9.8.2. Product Offerings
9.8.3. Financial Performance
9.8.4. Recent Initiatives
Chapter 10. Research Methodology
10.1. Primary Research
10.2. Secondary Research
10.3. Assumptions
Chapter 11. Appendix
11.1. About Us
Glossary of Terms